Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR103 multiple-dose trial in active rheumatoid arthritis
NL-OMON36374Phase 2Active, not recruiting
- Sponsor
- MorphoSys AG
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing MOR103 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2010; status: active, not recruiting.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON36374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36374.